Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Next Deadline
31 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
August 20, 2025
Extension Available
Until February 20, 2025
Application History
22 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
May 8, 2025 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
May 8, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
Feb 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Feb 20, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Feb 19, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Feb 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Aug 19, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Aug 19, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Aug 19, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Aug 19, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Feb 20, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Dec 26, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Dec 26, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Dec 6, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Nov 17, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Nov 17, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Nov 17, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Nov 17, 2023 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
Nov 17, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Nov 14, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Mar 6, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Feb 18, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
Class 040
Custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells, in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease
Class 042
medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of, therapeutic targets for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of cancer, inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information relating to treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services
Additional Information
Pseudo Mark
A TWO BIO
Classification
International Classes
005
040
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"